DopaSnap

**DopaSnap** is an oral fixed-dose immediate-release tablet formulation of **carbidopa + levodopa** developed by **Riverside Pharmaceuticals**. Publicly verifiable evidence for this product comes from a registered Phase 1 bioequivalence and food-effect study evaluating **DopaSnap 25 mg/100 mg tablet** against a marketed carbidopa/levodopa 25 mg/100 mg comparator in healthy volunteers. Pharmacologically, levodopa serves as a dopamine precursor that is converted centrally to dopamine to improve motor symptoms of Parkinsonism, while carbidopa inhibits peripheral aromatic L-amino acid decarboxylase, reducing peripheral levodopa metabolism and increasing levodopa delivery to the brain. Based on the available public record, DopaSnap appears to be a branded formulation product rather than a novel molecular entity.

Brand names

DopaSnap

Other names

carbidopa + levodopacarbidopa/levodopa